Nature Medicine, Published online: 19 August 2026; doi:10.1038/s41591-026-04605-1
In an early-stage randomized trial, the safety and efficacy of intramyocardial injection of hiPSC-derived cardiomyocytes in patients with advanced heart failure were evaluated.
